Sichenzia Ross Friedman Ference LLP Acted as Placement Agent Counsel on MabVax Therapeutic’s $11.7M PIPE
New York, NY – April 17, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that Axiom Capital Management Inc. has completed a private placement of MabVax Therapeutics Holdings, Inc. (OTC: MBVX) Units. MabVax is a clinical-stage biopharmaceutical company focused on developing vaccine and monoclonal anti-body based therapeutics. The private placement consisted of 15,486,001 Units offered at $0.75 per Unit for aggregate proceeds of $11,714,501. Additionally, each Unit consisted of one share of common stock and a 30-month warrant to purchase one-half of one share of common stock where the warrants are exercisable at $1.50 per each whole share of common stock.
The private placement was led by OPKO Health, Inc. (NYSE: OPK) and the Frost Gamma Investments Trust. Sichenzia Ross Friedman Ference LLP Partners Harvey Kesner, Tara Guarneri-Ferrara, Associate Tim O’Brien and Foreign Attorney Ekaterina Williams represented Axiom Capital Management.
To learn more about SRFK, visit www.srfkllp.com, SRFK’s LinkedIn and our Twitter page: @SRFKLLP
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner Associate Cass Sanford Quoted in Business Insider Article on Topics Surrounding Reg A+ - May 12, 2017
- Sichenzia Ross Ference Kesner LLP Celebrates its 19th Anniversary - May 9, 2017
- Sichenzia Ross Ference Kesner LLP Advises PolarityTE, Inc. on Acquisition of Intellectual Property Related to Regenerative Medicine - May 7, 2017